New Immune-Boosting drug tested with chemo to fight advanced sarcoma
NCT ID NCT04577014
Summary
This study is testing whether adding an experimental immunotherapy drug called retifanlimab to standard chemotherapy (gemcitabine and docetaxel) is safe and more effective for treating advanced soft tissue sarcoma. The goal is to see if the combination can better control the cancer and stop it from growing. The trial is for adults with advanced sarcoma that cannot be removed by surgery and who have not had prior treatment for their advanced disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.